UCLA Hematology/Oncology- Westlake

Westlake Village, California 91361

2 studies enrolling now · 8 studies all time

What they study most

Breast Cancer, Breast Neoplasms, Cancer of the Prostate, HER2 Positive Breast Cancer, Hormone Sensitive Prostate Cancer, Melanoma, Metastatic Castration Sensitive Prostate Cancer (mCSPC), Prostate Cancer, Urothelial Carcinoma

Studies at this site

• This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. — Recruiting now
• A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 — Recruiting now
• A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer — Running, not enrolling
• Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 — Running, not enrolling
• Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease — Running, not enrolling
• A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer — Completed
• A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2) — Completed
• A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma — Completed